Our results indicate that although there were significant differences in serum AAT levels between the PI*SS and PI*SZ genotypes, there were no significant differences in clinical manifestations, i.e. the prevalence of emphysema, COPD, asthma, bronchiectasis, or differences in lung function or quality of life, after careful matching for confounders. This evidence concerns the gene SERPINA1 and bronchiectasis.